A new landmark clinical trial shows that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
Apr 15, 2019
0
472
A drug therapy used for patients with chronic heart failure also improves markers of poor prognosis in individuals who are hospitalized with acute heart failure, new Yale-led research shows. The findings suggest that the ...
Nov 11, 2018
1
30
Boosting levels of a specific protein in the brain alleviates hallmark features of Alzheimer's disease in a mouse model of the disorder, according to new research published online August 25, 2016 in Scientific Reports.
Aug 25, 2016
0
295
Medicine focuses almost entirely on fighting chronic diseases in a piecemeal fashion as symptoms develop. Instead, more efforts should be directed to promoting interventions that have the potential to prevent multiple chronic ...
Jul 23, 2014
0
0
An international group of scientists has shown that a drug candidate designed by scientists from the Florida campus of The Scripps Research Institute (TSRI) significantly increases exercise endurance in animal models.
Jul 14, 2013
0
0
(Medical Xpress) -- Though rats, fish oil and beetroot juice read like ingredients in a witch's brew, to a Kansas State University research team, information from this combination could lead to health breakthroughs for aging ...
Jul 22, 2011
0
0
A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization ...
Apr 25, 2024
0
35
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified the mechanisms through which anthracyclines, a widely used class of anticancer drugs, damage the hearts of patients receiving this ...
Apr 16, 2024
0
0
While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
0
A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic cardiovascular disease (ASCVD), ...
Apr 8, 2024
0
0
